Comparative Pharmacology
Head-to-head clinical analysis: SLO BID versus VOSPIRE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SLO BID versus VOSPIRE ER.
SLO-BID vs VOSPIRE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Relaxes smooth muscle of bronchial airways and pulmonary blood vessels by inhibiting phosphodiesterase, increasing intracellular cAMP, and promoting bronchodilation.
Vospire ER (albuterol sulfate) is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via activation of adenylyl cyclase, leading to bronchodilation.
Dose: 300-600 mg orally every 12 hours. Immediate-release: 5 mg/kg loading dose then 3 mg/kg every 6 hours. Extended-release: 10-15 mg/kg/day divided every 12 hours. Titrate to serum theophylline concentration of 5-15 mcg/mL.
Oral: 30-60 mg once daily in the morning, with or without food. Maximum dose: 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: 3-15 hours (mean ~10 hours in adults; 20-30 hours in neonates; 1-5 hours in smokers). Clinically, half-life decreases with smoking, increases with hepatic disease, heart failure, and certain drugs (e.g., cimetidine, ciprofloxacin).
Terminal elimination half-life of vospire ER is approximately 12-15 hours. This prolonged half-life supports once-daily dosing and provides sustained bronchodilation over the dosing interval.
Renal: 90% as metabolites (caffeine, theobromine, paraxanthine, and unchanged drug; 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine). Biliary/fecal: <10%.
Primarily renal (approximately 75% as unchanged drug and metabolites) and biliary/fecal (approximately 25%).
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator